ADC Therapeutics is thrilled to announce a monumental funding milestone, having raised $100,000,000 to further accelerate our mission to transform lives affected by cancer. As a global pioneer and commercial-stage leader in the field of antibody drug conjugates (ADCs), our company has consistently pushed the boundaries of innovation in oncology. This significant infusion of capital will be strategically utilized to expand and refine our robust ADC portfolio, targeting breakthrough treatment opportunities in both hematology and solid tumors. By leveraging our unique, validated technology platform and cutting-edge next-generation research and development toolbox, we plan to pursue multiple targets concurrently, ensuring that we continue to build on our proven track record, including our FDA accelerated and European Commission conditional approvals for our CD19-directed ADC ZYNLONTA庐.
Founded in 2011 and headquartered in Lausanne, Switzerland with additional operations in London and New Jersey, ADC Therapeutics is committed to a disciplined capital allocation strategy that not only accelerates our ongoing pipeline developments but also positions us to become the leading ADC company in the fight against cancer. The raised funds will enable us to fortify our collaboration with strategic partners, invest in advanced research initiatives and expand our reach in pursuing next-generation therapies. We remain dedicated to conquering the challenges of cancer treatment and improving patient outcomes by transforming breakthrough science into transformative therapies. This achievement marks a pivotal step in our journey towards offering renewed hope and therapeutic options to patients worldwide. For more details about our advancements and strategic vision, please visit our website at https://www.adctherapeutics.com/.
